| Indicators | Browse All

ImmunityBio, Inc. (IBRX)

Healthcare | Biotechnology | San Diego, United States | NasdaqGS
7.79 USD -0.43 (-5.231%) ⇩ (July 13, 2026, 4 p.m. EDT)
After hours: 7.78 -0.01 (-0.010%) ⇩ (July 13, 2026, 7:59 p.m. EDT)

Short-term:★★★⯪☆Long-term:★⯪☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 4:13 a.m. EDT

The immediate outlook is defined by a tense standoff between aggressive retail speculation and deep institutional hedging. While the stock has rallied significantly off its lows, the underlying business remains in a precarious state with negative free cash flow, a massive debt load relative to cash, and a history of severe multi-year declines. The recent price action is driven entirely by hope surrounding a specific clinical trial (Anktiva-NK) and potential index inclusion, rather than sustainable operational improvements. The options market confirms this fragility: traders are buying cheap calls for a speculative pop but have erected formidable put walls to protect against a return to the $4-$7 range. Until the company demonstrates a path to profitability or a definitive regulatory milestone that de-risks the pipeline, this remains a high-risk speculative vehicle where the odds favor a continued struggle to find a stable floor rather than a fundamental recovery.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL_79_115 ✓0.068445
AutoARIMA0.069433
AutoETS0.069434
AutoTheta0.069764
MSTL0.069850
MSTL_790.169383
MSTL_1150.197718

Forecast horizon: 60 days | Selected: MSTL_79_115

Forecast Reliability
Score 32%
H-stat 1.81
Ljung-Box p 0.000
Jarque-Bera p 0.112
Excess Kurtosis -0.05
Attribute Value
Sector Healthcare
Revenue per Share 0.146
Market Cap 8,158,887,424
Forward P/E 129.83
Beta 0.08
Website https://immunitybio.com

As of July 11, 2026, 4:13 a.m. EDT: Speculators are positioning for a volatile range-bound outcome rather than a decisive breakout. Call volume is heavily skewed toward out-of-the-money strikes (9.0 and 10.0), suggesting bets on a rally to the $10-$12 zone, while massive put open interest walls exist at 7.5 and 4.0, indicating a strong defense of the current floor. The disparity between high call volume and lower put volume suggests a bullish bias, but the heavy concentration of options at specific strikes implies the market expects a choppy grind rather than a free-fall or a moonshot.


Info Dump

Attribute Value
52 Week Change 1.8344827
Address1 3,530 John Hopkins Court
All Time High 45.42
All Time Low 0.93
Ask 39.9
Ask Size 38
Audit Risk 6
Average Daily Volume10 Day 15,602,970
Average Daily Volume3 Month 13,709,901
Average Volume 13,709,901
Average Volume10Days 15,602,970
Beta 0.077
Bid 5.79
Bid Size 2
Board Risk 8
Book Value -0.831
City San Diego
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 9
Country United States
Crypto Tradeable 0
Currency USD
Current Price 7.79
Current Ratio 6.666
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 8.15
Day Low 7.73
Display Name ImmunityBio
Earnings Timestamp 1,778,157,000
Earnings Timestamp End 1,785,846,600
Earnings Timestamp Start 1,785,846,600
Ebitda -245,412,992
Ebitda Margins -1.7408
Enterprise To Ebitda -36.28
Enterprise To Revenue 63.156
Enterprise Value 8,903,496,704
Eps Forward 0.06
Eps Trailing Twelve Months -0.85
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 7.7895
Fifty Day Average Change 0.00049972534
Fifty Day Average Change Percent 0.00006415371
Fifty Two Week Change Percent 183.44827
Fifty Two Week High 12.43
Fifty Two Week High Change -4.6400003
Fifty Two Week High Change Percent -0.37329045
Fifty Two Week Low 1.95
Fifty Two Week Low Change 5.84
Fifty Two Week Low Change Percent 2.9948719
Fifty Two Week Range 1.95 - 12.43
Financial Currency USD
First Trade Date Milliseconds 1,438,090,200,000
Float Shares 394,161,196
Forward Eps 0.06
Forward P E 129.83333
Free Cashflow -193,704,624
Full Exchange Name NasdaqGS
Full Time Employees 684
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,782,864,000
Gross Margins 0.99337995
Gross Profits 140,044,000
Has Pre Post Market Data 1
Held Percent Insiders 0.62473
Held Percent Institutions 0.17641
Implied Shares Outstanding 1,047,353,977
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Long Name ImmunityBio, Inc.
Market us_market
Market Cap 8,158,887,424
Market State PREPRE
Max Age 86,400
Message Board Id finmb_303022599
Most Recent Quarter 1,774,915,200
Net Income To Common -854,534,016
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 8,609,249,690
Number Of Analyst Opinions 3
Open 8.05
Operating Cashflow -294,390,016
Operating Margins -1.57877
Overall Risk 8
Payout Ratio 0.0
Phone 844 696 5235
Post Market Change -0.009999752
Post Market Change Percent -0.12836652
Post Market Price 7.78
Post Market Time 1,783,987,185
Previous Close 8.22
Price Hint 2
Price To Book -9.3742485
Price To Sales Trailing12 Months 57.873894
Profit Margins 0.0
Quick Ratio 6.242
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.43
Regular Market Change Percent -5.23115
Regular Market Day High 8.15
Regular Market Day Low 7.73
Regular Market Day Range 7.73 - 8.15
Regular Market Open 8.05
Regular Market Previous Close 8.22
Regular Market Price 7.79
Regular Market Time 1,783,972,801
Regular Market Volume 9,831,731
Return On Assets -0.34379002
Revenue Growth 1.676
Revenue Per Share 0.146
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 6
Shares Outstanding 1,047,353,977
Shares Percent Shares Out 0.1259
Shares Short 131,830,884
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 132,143,163
Short Name ImmunityBio, Inc.
Short Percent Of Float 0.3394
Short Ratio 9.91
Source Interval 15
State CA
Symbol IBRX
Target High Price 15.0
Target Low Price 12.0
Target Mean Price 13.0
Target Median Price 12.0
Total Cash 380,879,008
Total Cash Per Share 0.364
Total Debt 1,124,608,000
Total Revenue 140,976,992
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.85
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 5.545825
Two Hundred Day Average Change 2.244175
Two Hundred Day Average Change Percent 0.40466025
Type Disp Equity
Volume 9,831,731
Website https://immunitybio.com
Zip 92,121